MLN-9708

MLN-9708 is a prodrug of Ixazomib citrate (MLN-2238). MLN-9708 is an orally bioavailable next-generation proteasome inhibitor (PI) with potential potent anticancer activity in both hematologic and solid tumor xenograft models with better pharmacokinetic and pharmacodynamic features than PS-341 (Cat. No. 1846).